Cerdulatinib
Cerdulatinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK1, NUAK family SNF1-like kinase 1, non-receptor tyrosine-protein kinase TYK2, tyrosine-protein kinase SYK, mitogen-activated protein kinase kinase kinase 9, macrophage colony-stimulating factor 1 receptor, tyrosine-protein kinase JAK2, tyrosine-protein kinase JAK3, and serine/threonine-protein kinase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | 1 | — | — | 2 |
| T-cell lymphoma | D016399 | — | — | 1 | 2 | 1 | — | — | 2 |
| Follicular lymphoma | D008224 | — | C82 | 1 | 2 | 1 | — | — | 2 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | — | 1 | 1 | — | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | 1 | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 1 | — | — | 1 | 2 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 1 | — | — | — | 1 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cerdulatinib |
| INN | cerdulatinib |
| Description | Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1198300-79-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4116008 |
| ChEBI ID | — |
| PubChem CID | 44595079 |
| DrugBank | — |
| UNII ID | D1LXQ45S1O (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
JAK1
JAK1
NUAK1
NUAK1
TYK2
TYK2
SYK
SYK
MAP3K9
MAP3K9
CSF1R
CSF1R
JAK2
JAK2
JAK3
JAK3
STK4
STK4
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 264 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use